Abstract
Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease. Emerging evidence suggests that the chronic systemic inflammation may predispose patients to an increased risk of malignancy. Despite this, information on cancer occurrence in patients with HS is scarce, and no meta-analysis has explored which types of cancer are more prevalent in patients with HS.
Methods
PubMed, Embase, and Web of Science were searched from inception until 7 March 2025 for studies investigating the risk of cancer in patients with HS compared with the general population. In addition, authors of unpublished studies (e.g., conference abstracts) were contacted for data retrieval.
Studies had to report the number and/or risk of cancer overall or subtypes of cancer in patients with HS compared with the general population. Two independent authors conducted the screening and extracted data.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. An inverse-variance-weighted random-effects meta-analysis was performed to calculate pooled odds ratio (ORs) and corresponding 95% confidence interval (CIs).
The prespecified primary outcome was the risk of cancer overall and subtypes of cancer in patients with HS compared with the general population.
Results
A total of 11 studies encompassing 624,721 patients with HS and 393,691,636 controls were included. Compared with controls, patients with HS had a significantly elevated risk of cancer overall (OR: 1.82; 95% CI 1.13–2.93; p = 0.018) and of gastrointestinal (OR: 1.61; 95% CI 1.29–2.01; p = 0.0002), head and neck (OR: 2.41; 95% CI 1.92–3.02; p = 0.00005), hematological (OR: 1.71; 95% CI 1.38–2.12; p = 0.00005), respiratory cancers (OR: 1.81; 95% CI 1.03–3.17; p = 0.04), Hodgkin lymphoma (OR: 2.44; 95% CI 1.55–3.85; p = 0.0001), and non-Hodgkin lymphoma (OR: 1.15; 95% CI 1.03–1.29; p = 0.01). Few studies reported estimates adjusted for ethnicity and environmental risk factors.
Conclusions
Having HS was associated with an increased risk of cancer overall, including several specific subtypes. Studies adjusting for confounders are highly warranted to assess the long-term association between HS and cancer.
Supplementary Information
The online version contains supplementary material available at 10.1007/s13555-026-01697-y.
Keywords: Cancer, Hidradenitis suppurativa, Leukemia, Malignancy, Melanoma, Neoplasm
Plain Language Summary
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition primarily affecting areas with skin friction, e.g., armpits, groin, and under the breasts. The lesions can leak fluid, become infected, and often leave scars. HS affects about 1 in 100 people. We wanted to find out whether people with HS are more likely to develop cancer than people in the general population. Previous research has suggested that there may be a higher risk, but it is unclear whether this stems from an overall increased risk of cancer or whether it is caused by a higher frequency of particular types of cancer. To explore this, we pooled results from existing studies of the risk of cancer in patients with HS compared with the general population. We found that people with HS had a higher overall risk of cancer compared with the general population, but also that certain types of cancer such as abdominal, head and neck, respiratory, and hematological cancers were more common in patients with HS. These findings suggest that people with HS may have an increased risk of certain cancers. However, we also stress that most people with HS will not get cancer, and the overall risk remains low. Our study highlights the importance of ongoing care and monitoring for people living with HS.
Supplementary Information
The online version contains supplementary material available at 10.1007/s13555-026-01697-y.
Key Summary Points
| Why carry out this study? |
| Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease primarily affecting the intertriginous areas. |
| Observational studies have explored the incidence of various cancers in patients with HS, finding elevated risks of squamous-cell carcinoma, lymphoma, and lung cancer. |
| Results have been inconsistent, and it is debated whether an increased risk of cancer overall and subtypes of cancer is attributable to HS itself or associated comorbidities. |
| What was learned from the study? |
| In this meta-analysis of 11 studies encompassing more than 600,000 patients with HS and approximately 400 million controls, patients with HS had a significantly elevated risk of cancer overall, as well as of gastrointestinal, head and neck, hematological, and respiratory cancers and of Hodgkin and non-Hodgkin lymphoma. |
| Studies adjusting for confounding factors such as smoking, body mass index (BMI), and alcohol intake are highly needed. |
Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder characterized by painful nodules, abscesses, and skin tunnel formation, primarily affecting intertriginous areas [1]. The disease has a profound impact on quality of life and is often associated with significant comorbidities, including metabolic syndrome, depression, and inflammatory bowel disease [2–6]. Emerging evidence suggests that the chronic systemic inflammation observed in HS may predispose patients to an increased risk of malignancy [7–9]. This potential association has drawn growing attention, particularly in light of similar findings in other chronic inflammatory conditions such as psoriasis [10] and rheumatoid arthritis [11].
Several observational studies have explored the incidence of a diverse set of cancers in patients with HS, finding elevated risks of squamous-cell carcinoma, lymphoma, and lung cancer [7–9]. However, results across studies have been inconsistent, and it is debated whether an increased risk is attributable to HS itself or to associated comorbidities such as an elevated body mass index (BMI) and smoking. Furthermore, which organ systems may exhibit an elevated cancer risk in patients with HS remains to be elucidated.
Given the clinical importance of understanding long-term risks associated with HS, a comprehensive analysis of available evidence is highly warranted. This meta-analysis aims to evaluate the risk of overall cancer and subgroups of cancer in patients with HS compared with controls from the general population, thereby providing a clearer understanding of cancer risk in this patient population. Special attention has been given to which organ system contributes the most to the overall cancer risk of patients with HS.
Methods
Protocol and Registration
This systematic review was conducted following the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251001689).
Data Sources and Search Strategy
Two authors (D.I. and R.K.A.) independently and systematically screened three electronic databases, PubMed, Embase, and Web of Science, from inception until 7 March 2025. A search strategy was developed using the following search string: “((hidradenitis suppurativa) OR (acne inversa) OR (Verneuil’s disease)) AND ((Neoplasms) OR (malignancy) OR (cancer) OR (melanoma) OR (carcinoma) OR (lymphoma) OR (leukemia) OR (sarcoma) OR (myeloma) OR (blastoma)).”
Study Selection and Data Extraction
All search results from the three databases were imported into the online screening platform Rayyan [12], facilitating independent, blinded initial screening based on titles and abstracts by two authors (D.I. and R.K.A.). Conflicts or discrepancies in screening outcomes were resolved through discussion and consensus with a third author (M.B.J.). Following initial screening, full-text articles were assessed for eligibility. Additionally, reference lists of eligible studies were manually searched to identify any further relevant studies. Eligible studies were required to report cancer incidence in populations diagnosed with HS compared with the general population. All study designs and languages were eligible.
Data were extracted into a predefined structured table, including author(s), publication year, title, country, study design, number of cancer cases in both the HS and general populations, total population sizes, sex distribution, age, body mass index (BMI), smoking status, International Classification of Diseases (ICD) codes, effect measures (odds ratio [OR], hazard ratio [HR], standardized incidence ratio [SIR]), effect estimates, and corresponding confidence intervals (CI).
Statistical Analysis
Statistical analyses were conducted using R Studio software (version 2024.12.1). An inverse-variance-weighted random-effects meta-analysis using the DerSimonian and Laird method was performed to calculate pooled ORs and corresponding 95% CIs. A random-effects model was applied due to substantial heterogeneity among studies. Heterogeneity was assessed using the Cochrane Q test and I2 statistic. Forest plots were generated to visually present individual study and pooled effect sizes. Funnel plots were used to qualitatively assess publication bias.
As included studies reported diverse outcome measures, these were standardized to ORs to facilitate comparability across studies. Conversion to ORs allowed the inclusion of data from studies originally reporting HRs or SIRs, ensuring minimal information loss due to the generally large sample sizes of these studies. An overall combined risk estimate for cancer associated with HS was extracted directly if provided or calculated using available raw data by pooling cases from each study. Cancers were categorized into the following groups for subgroup analysis: bone and soft-tissue cancers, breast cancer, central nervous system cancers, endocrine-related cancers, gastrointestinal cancers, head and neck cancers, hematological cancers, respiratory system cancers, skin cancers, urogenital cancers, and unspecified cancers. The number of times cancer belonging to each of the categorized subgroups had been investigated was noted for further analysis.
A subanalysis with adjusted OR (aOR) was performed on studies reporting results adjusted for more than just sex and age.
Study Quality Assessment
The methodological quality and risk of bias of included studies were assessed using the Newcastle–Ottawa Scale (NOS), so a maximum of 9 points could be given. Scores ≥ 7 were considered good quality, and scores < 7 were considered lower study quality.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Results
Eligible Studies
Overall, 2102 articles (PubMed = 638, Embase = 768, Web of Science = 696) were included. After removing 854 duplicates, 1248 nonduplicate articles were assessed for inclusion based on title and abstract. Of these, 30 full-text articles were assessed for inclusion. After the full-text assessment, 19 articles were excluded with reasons, yielding 11 articles[7–9, 13–20] included for quantitative analysis. The authors of two conference abstracts were contracted via e-mail, but only information from one of the unpublished articles [20] was retrieved through the corresponding author. No new studies were retrieved after examination of the reference lists of included studies (Fig. S1).
Characteristics of the Included Studies
A total of 11 studies [7–9, 13–20] published between 2001 and 2024 were included. The studies included a total of 624,721 patients diagnosed with HS. Study sizes varied widely, ranging from 716 participants with HS [17] to 390,522 [14]. The general population or control groups comprised a total of 393,691,636 participants, with numbers ranging from 1730 [18] to 106,900,000 [20]. The mean age of HS participants was reported in six studies [7–9, 17–19] and varied from 33.6 years [8] to 43.8 years [18].
BMI data were not reported in any of the included studies. Smoking prevalence among patients with HS ranged from 4.2% [13] to 29.5% [18]. In control groups, smoking prevalence ranged from 0.92% [18] to 6.70% [19]. Ethnicity was also inconsistently reported. Identified ethnic groups included White, Black or African American, Asian, and Hispanic populations [13, 15]. Due to inconsistencies and lack of standardization, a comprehensive summary of ethnicity across all studies was not feasible. The studies originated from the USA (n = 8 studies [13–20]), Sweden (n = 1 study [7]), Denmark (n = 1 study[9]), and Korea (n = 1 study [8]) (Table S1).
According to the NOS tool, the overall methodological quality and risk of bias were assessed as low or acceptable across the included studies. Overall, the methodological quality was considered sufficient to support the reliability of the findings (Table S2).
Risk of Cancer in Patients with HS Compared with the General Population
An overview of the association between the risk of cancer in patients with HS compared with healthy controls is available in Table 1 and Fig. 1.
Table 1.
Unadjusted risk of cancer overall and individual cancers in patients with HS compared with the general population
| Cancer | Studies (n) | Population with HS (n) | HS with cancer (n) | General population (n) | General population with cancer (n) | OR (95% CI) | I2 | Tau2 | p-Value |
|---|---|---|---|---|---|---|---|---|---|
| Overall | 11 | 624,721 | 5589 | 393,817,206 | 2,260,242 | 1.82 (1.13–2.93) | 0.99 | 0.40 | 0.0183 |
| Bone and soft-tissue cancers | 2 | 36,387 | 9 | 9,775,685 | 5024 | 1.06 (0.31–3.61) | 0.00 | 0.00 | 0.64 |
| Breast cancer | 3 | 38,506 | 294 | 21,821,642 | 215,617 | 1.06 (0.85–1.33) | 0.00 | 0.00 | 0.36 |
| Central nervous system cancers | 3 | 38,506 | 79 | 21,821,642 | 49,900 | 1.33 (0.84–2.10) | 0.30 | 0.04 | 0.16 |
| Endocrine-related cancers | 2 | 36,387 | 66 | 9,775,685 | 8995 | 1.11 (0.68–1.82) | 0.00 | 0.00 | 0.46 |
| Gastrointestinal cancers | 3 | 38,506 | 409 | 21,821,642 | 136,884 | 1.61 (1.29–2.01) | 0.60 | 0.08 | 0.0002 |
| Head and neck cancers | 3 | 38,506 | 145 | 21,821,642 | 43,852 | 2.41 (1.92–3.02) | 0.10 | 0.01 | 0.00001 |
| Hematological cancers | 7 | 105,888 | 602 | 51,079,708 | 207,167 | 1.71 (1.38–2.12) | 0.70 | 0.12 | 0.00005 |
| Lymphomaa | 4 | 27,160 | 79 | 499,920 | 3291 | 1.75 (0.98–3.13) | 0.61 | 0.22 | 0.06 |
| Hodgkin lymphoma | 3 | 99,077 | 122 | 38,713,565 | 28,453 | 2.44 (1.55–3.85) | 0.53 | 0.09 | 0.0001 |
| Non-Hodgkin lymphoma | 3 | 99,077 | 304 | 38,713,565 | 127,012 | 1.15 (1.03–1.29) | 0 | 0 | 0.01 |
| Respiratory system cancers | 3 | 38,506 | 300 | 21,821,642 | 91,239 | 1.81 (1.03–3.17) | 0.80 | 0.16 | 0.04 |
| Skin cancers | 8 | 560,155 | 3756 | 364,744,946 | 1,517,399 | 1.48 (0.94–2.31) | 0.90 | 0.05 | 0.08 |
| Non-melanoma skin cancer | 7 | 495,345 | 2226 | 257,844,946 | 789,926 | 1.70 (0.90–3.19) | 0.93 | 0.48 | 0.08 |
| Squamous-cell carcinoma | 5 | 521,649 | 1506 | 342,923,304 | 534,743 | 2.80 (0.64–11.76) | 0.99 | 0.29 | 0.13 |
| Basal-cell carcinoma | 3 | 467,226 | 1106 | 245,300,229 | 472,314 | 1.79 (0.62–5.14) | 0.96 | 0.85 | 0.27 |
| Melanoma | 5 | 491,813 | 1230 | 257,844,946 | 520,647 | 1.35 (0.65–2.84) | 0.88 | 0.54 | 0.41 |
| Urogenital cancers | 4 | 39,222 | 396 | 21,954,862 | 236,577 | 1.17 (0.95–1.44) | 0.60 | 0.08 | 0.13 |
| Unspecified cancers | 1 | 13,919 | 50 | 9,595,951 | 17,187 | 2.00 (0.68–5.90) | 0.00 | 0.00 | 0.08 |
p < 0.05 are marked bold. CI, confidence interval; HS, hidradenitis suppurativa; OR, odds ratio
aCould not be further specified as either Hodgkin or Non-Hodgkin lymphoma in the original articles and were therefore analyzed as a separate group
Fig. 1.
Cancer risk in hidradenitis suppurativa: overall and organ-specific analysis. Illustration of overall and organ-specific cancer risks in hidradenitis suppurativa, with arrows indicating affected sites and associated risk estimates. Created with BioRender.com. CI, confidence interval; OR, odds ratio
The risk of cancer overall was assessed via 11 studies [7–9, 13–20], revealing a crude OR of 1.82 (95% CI 1.13–2.93; p = 0.018) when comparing 624,721 patients with HS with 5589 cancers with 393,817,206 people from the general population with 2,260,242 cancers (Figs. 1, 2; Fig. S2).
Fig. 2.
Forest plot of cancer overall. Each horizontal line represents an individual study included in the meta-analysis, with the square indicating the study-specific effect estimate and the size of the square proportional to the study’s weight. The horizontal lines denote 95% CI. The diamond at the bottom represents the overall pooled effect estimate with its 95% CI. CI, confidence interval; HS, hidradenitis suppurativa (HS); OR, odds ratio
An increased risk of several categories of cancer was found. For gastrointestinal cancers, the crude OR was 1.61 (95% CI 1.29–2.01; p = 0.0002) based on three studies [7–9]. For head and neck cancers, the crude OR was 2.41 (95% CI 1.92–3.02; p = 0.00001) based on three studies [7–9]. For hematological cancers, the crude OR was 1.71 (95% CI 1.38–2.12; p = 0.00005) based on seven studies [7–9, 13, 16, 18, 19]. For respiratory system cancers, the crude OR was 1.81 (95% CI 1.03–3.17; p = 0.04) based on three studies [7–9] (Fig. 1; Fig. S3).
For lymphoma, the crude OR was 1.75 (95% CI 0.98–3.13; p = 0.058) based on four studies [8, 13, 18, 19]. Not all studies contained detailed information on the different types of lymphoma included, and some provided aggregated lymphoma outcomes (including cutaneous lymphoma). Thus, detailed analyses for risk of Hodgkin lymphoma and non-Hodgkin lymphoma were only derived from three studies [8, 9, 16]. These analyses found an elevated risk for both Hodgkin lymphoma (OR: 2.44; 95% CI 1.55–3.85; p = 0.0001) and non-Hodgkin lymphoma (OR: 1.15; 95% CI 1.03–1.29; p = 0.012) (Figs. 1, 3).
The crude OR of skin cancer was higher for HS although not statistically significant (OR: 1.48; 95% CI 0.94–2.31]; p = 0.08). In subanalyses of individual skin cancers, neither basal-cell carcinoma (OR: 1.79; 95% CI 0.62–5.14; p = 0.27), squamous-cell carcinoma (SCC) (OR: 2.80; 95% CI 0.64–11.76; p = 0.13), nor melanoma (OR: 1.35; 95% CI 0.65–2.84; p = 0.41) were found to be significantly increased in patients with HS (Figs. 1, 3).
No tendencies toward increased risk of bone and soft-tissue cancers (OR: 1.06; 95% CI 0.31–3.61; p = 0.64), central nervous system cancers (OR: 1.33; 95% CI 0.84–2.10; p = 0.16), breast cancer (OR: 1.06; 95% CI 0.85–1.33; p = 0.36), urogenital cancers (OR: 1.17; 95% CI 0.95–1.44; p = 0.13), or unspecified cancers (OR: 2.0; 95% CI 0.68–5.90; p = 0.08) were found (Figs. 1, 3).
Risk of Cancer in Patients with HS Compared with the General Population When Accounting for Potential Confounding Factors
A total of four studies [8, 13, 15, 18] reported estimates of subtypes of cancer after adjusting for factors other than age and sex. Of these, one study [13] adjusted for race, ethnicity, and comorbidities; one study [18] adjusted for smoking, obesity and comorbidities; one study [15] adjusted for age, ethnicity and race, sex and insurance type; and another [8] adjusted for comorbidities. Meta-analysis of aOR for cancer overall could not be conducted due to inconsistent reporting.
For lymphoma, the aOR was 1.31 (95% CI 0.56–3.04; p = 0.30) based on three studies [8, 13, 18] comparing 26,000 patients with HS developing 76 lymphomas with 498,760 controls developing 3284 lymphomas. In addition to being not statistically significant, the aORs for lymphoma were found comparable to the crude estimate. The same was the case for Hodgkin lymphoma (aOR: 2.44; 95% CI 0.07–75.6; p = 0.18), non-Hodgkin lymphoma (aOR: 1.96; 95% CI 0.61–6.22; p = 0.08), and cutaneous T-cell lymphoma (aOR: 4.17; 95% CI 0.73–23.71; p = 0.06) (Table 2).
Table 2.
Adjusted risk of cancer overall and individual cancers in patients with HS compared with the general population
| Cancer | Studies (n) | Population with HS (n) | HS with cancer (n) | General population (n) | General population with cancer (n) | Adjusted OR (95% CI) | I2 | Tau2 | p-Value |
|---|---|---|---|---|---|---|---|---|---|
| Lymphomaa | 3 | 26,000 | 76 | 498,760 | 3284 | 1.31 (0.56–3.04) | 0.34 | 0.06 | 0.30 |
| Hodgkin lymphoma | 2 | 85,158 | 108 | 29,117,614 | 25,340 | 2.44 (0.07–75.6) | 0.21 | 0.07 | 0.18 |
| Non-Hodgkin lymphoma | 2 | 85,158 | 258 | 29,117,614 | 102,617 | 1.96 (0.61–6.22) | 0.05 | 0.005 | 0.08 |
| Cutaneous T-cell lymphoma | 2 | 125,475 | 79 | 119,754,656 | 24,557 | 4.17 (0.73–23.71) | 0 | 0 | 0.06 |
| Squamous-cell carcinoma | 2 | 64,587 | 1146 | 91,134,072 | 483,245 | 2.50 (1.87–3.35) | 0.98 | 4.13 | < 0.0001 |
| Melanoma | 2 | 85,253 | 13 | 90,996,510 | 3733 | 1.03 (0.14–7.30) | 0.0 | 0 | 0.20 |
CI, confidence interval; HS, hidradenitis suppurativa; OR, odds ratio
aCould not be further specified as either Hodgkin or non-Hodgkin lymphoma in the original articles and were therefore analyzed as a separate group
Two studies[13, 15] comparing 64,587 patients with HS developing 1146 SCCs with 91,134,072 controls developing 483,245 SCCs yielded an aOR of 2.50 (95% CI 1.87–3.35; p < 0.0001), while two studies comparing 85,253 patients with HS with 13 melanomas with 90,996,510 controls with 3,733 melanomas yielded an aOR of 1.03 (95% CI 0.14–7.30; p = 0.20) (Table 2).
Discussion
This systematic review and meta-analysis of 11 studies encompassing 624,721 patients with HS and 393,817,206 controls found that patients with HS had a significantly elevated risk of cancer overall and in particular of gastrointestinal, head and neck, hematological, and respiratory cancers and Hodgkin lymphoma and non-Hodgkin lymphoma when compared with controls from the general population.
We observed an elevated OR of cancer overall, consistent with prior findings from large registry-based studies. Here, a Swedish study reported a 50% elevated risk of cancer overall [7], with similar findings by a Danish study (40% increase [9]), and a Korean study (30% increase [8]). Discrepancies may rely on methodology, population demographics, follow-up duration, and adjustment for confounders such as smoking and BMI. Furthermore, considerable heterogeneity was observed across studies, though random effects models were used to account for between-study variability. Nevertheless, the observed heterogeneity suggests that pooled estimates should be interpreted as overall trends rather than precise risk quantifications. While previous meta-analyses have assessed the risk of cancer in patients with HS [21, 22], these relied on studies with relatively small sample sizes or focused solely on one type of cancer. As cancer in patients with HS is an increasingly important area of interest for patients and clinicians, reporting the risk of cancer overall alongside cancer subtypes is essential. Notably, the current findings combined with previous studies underline an increased risk not only of cancer in patients with HS compared with controls from the general population but also of several individual cancer subtypes. Furthermore, our meta-analytic approach combines data across various settings and time periods, potentially capturing a broader spectrum of HS severity and comorbidity burden.
The reasons for the increased risk of the individual cancer subtypes are not fully understood and are most likely multifactorial. Chronic inflammation is a risk factor for carcinogenesis [23], and as HS is characterized by persistent cutaneous and systemic inflammatory activity, this may be a contributing factor. However, no severity-based or mechanistic data exist to support this in patients with HS, and such data are highly needed. However, no increased risk of skin cancers or melanoma was found, which underlines that lifestyle and metabolic risk factors may contribute to the increased risk of cancer. Additionally, HS is often associated with other comorbidities, including smoking [24, 25], alcohol abuse [2, 25], obesity [2], and cardiovascular disease [3, 26], that may synergistically contribute to carcinogenesis. Notably, most of the organ-specific cancers associated with HS are also associated with smoking, whereas most cancers not associated with smoking were not increased in HS [9, 27]. However, few of the included studies adjusted for confounding factors such as smoking, obesity, and alcohol intake. Thus, further studies are needed to investigate to which degree shared lifestyle and metabolic risk factors rather than disease-specific mechanisms alone lead to the increased risk of cancer. In those that specified this, significant associations between HS and cancer development were only found for SCC, indicating that the increased risk of cancer seen among patients with HS might be due to lifestyle factors. Interestingly, the crude risk of non-Hodgkin lymphoma, not commonly perceived as associated with smoking, was increased in HS. Interestingly, this is consistent with a previous study that found a crude OR of 3.4 for lymphoma in patients with HS. Moreover, this association with lymphoma was not significant in the single study adjusting for both BMI and smoking [18]. Furthermore, tendencies of increased HS severity to be associated with an increased risk of cancer have been presented [8], thus underlining the importance of the inflammatory burden of HS. This increased risk is suspected to be a result of chronic low-grade inflammation. Indeed, patients with psoriasis also have an increased risk of non-Hodgkin lymphomas, but it is debated whether this risk is caused by nonspecific immunosuppressive therapies [28]. These treatments have only recently been incorporated into HS management [29], and the association is more likely a result of HS than other external factors.
Contrary to smaller studies [7, 8], the subanalysis on skin cancer did not find an increased risk of non-melanoma skin cancer (NMSC) or melanoma. However, the between-study heterogeneity was high for individual cancer subgroups such as lymphoma and skin cancers and should be interpreted with caution. The interest in HS-related skin cancer was sparked by the notion that SCC arising from HS lesions could be more aggressive than SCC in people without HS [22]. Chronic low-grade inflammation, smoking, and human papillomavirus have previously been suggested to play a critical role in the development of SCC in patients with HS [30–32]. Unfortunately, none of the included studies on skin cancer specifically focused on cancers arising from HS lesions. Thus, studies on skin cancer in inflamed areas are highly needed to examine the effect of chronic inflammation. While our crude meta-analysis on SCC did not indicate an association, a meta-analysis of adjusted estimates found a 2.5-fold increased risk of SCC in patients with HS. However, this finding relies on only two studies and should be interpreted with caution, as the difference might just be attributable to a higher HS prevalence among African Americans [33]—a group who also suffer a higher degree of severe SCC once diagnosed, likely due to underdiagnosis [34, 35]. Thus, close monitoring of suspicious developments in HS lesions is essential considering the aggressive nature of SCC in patients with HS.
Future studies should aim to stratify risk by disease severity and immunosuppressive therapies, control for confounding lifestyle factors, and explore longitudinal associations between HS and specific cancer subtypes. Better understanding the interplay between HS-related inflammation, comorbidities, and malignancy risk will be critical to guiding cancer surveillance and preventative strategies in this vulnerable population.
The strengths of the current study are the extensive literature search including more than 600.000 patients with HS and approximately 400 million controls. Most of the included studies were large, population-based cohorts with robust control groups ensuring reflection of real-world settings where possible stratified analyses of cancer subtypes, thus providing insightful information on the risk of cancer subtypes in patients with HS. However, some limitations should be highlighted. Firstly, limited data on cancer subtypes hindered meta-analyses of less common cancer types, and the absence of reporting of anti-inflammatory treatment and disease severity resulted in lack of subanalyses based on this. Most studies originated from North America, thus enriching the results and possibly leading to bias. Furthermore, BMI was not reported in a single study, and ethnicity was poorly reported. Lastly, only few studies adjusted for important confounding variables associated with risk of cancer.
Conclusion
In this systematic review and meta-analysis, HS was associated with an increased overall risk of cancer, including several specific subtypes, compared with controls. However, studies are adjusting for confounders and assess long-term associations between HS and cancer risk are highly needed to investigate which factors contribute to this cancer risk.
Supplementary Information
Below is the link to the electronic supplementary material.
Author Contributions
Daniel Isufi: concept of design, data extraction, writing—original draft, project administration, and methodology. Mikkel Bak Jensen: concept of design, data extraction, statistical analysis, review of the manuscript, and methodology. Nikolai Loft: writing—review and editing, validation, and methodology. Rune Kjærsgaard Andersen: concept of design, writing—review and editing, validation, methodology, and supervision.
Funding
No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.
Data Availability
The data are available upon reasonable request from the corresponding author.
Declarations
Conflict of Interest
Daniel Isufi and Mikkel Bak Jensen report no conflict of interest. Nikolai Loft reports research grant funding from the Leo Foundation and reports that he has been a paid speaker for Eli Lilly, Janssen Cilag, and Sandoz. Rune Kjærsgaard Andersen reports research grant funding from the Leo Foundation and reports that his attendance at the 2022 Nordic Congress of DermatoVenerology was funded by Eli Lilly.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64. 10.1056/NEJMCP1014163. [DOI] [PubMed] [Google Scholar]
- 2.Kjærsgaard Andersen R, Jorgensen IF, Reguant R, Jemec GBE, Brunak S. Disease trajectories for hidradenitis suppurativa in the Danish population. JAMA Dermatol. 2020;156:780–6. 10.1001/JAMADERMATOL.2020.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GBE. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142–55. 10.1111/BJD.14024. [DOI] [PubMed] [Google Scholar]
- 4.Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371–6. 10.1111/JDV.12567. [DOI] [PubMed] [Google Scholar]
- 5.Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R. Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther. 2019;36:1672–83. 10.1007/S12325-019-00964-Z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):17–22. 10.1016/J.DET.2015.07.003. [DOI] [PubMed] [Google Scholar]
- 7.Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137:730–4. 10.1001/pubs.ArchDermatol.-ISSN-0003-987x-137-6-dst00132. [PubMed] [Google Scholar]
- 8.Jung JM, Lee KH, Kim YJ, Chang SE, Lee MW, Choi JH, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol. 2020;156(8):844–53. 10.1001/JAMADERMATOL.2020.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Andersen RK, Rostgaard K, Pedersen O, Jemec GBE, Hjalgrim H. Increased cancer incidence among patients with hidradenitis suppurativa—a Danish nationwide register study 1977–2017. Acta Oncol. 2024;63:220–8. 10.2340/1651-226X.2024.26182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421–9. 10.1001/JAMADERMATOL.2020.0024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Region Health Eur. 2023. 10.1016/j.lanepe.2023.100768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016. 10.1186/S13643-016-0384-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Roster K, Fleshner L, Farabi B, Safai B. Social determinants of health and comorbidities in hidradenitis suppurativa using an inclusive database. 2024 [cited 2025 May 8]. https://www.pagny.org/uploads/images/headshots/Social-Determinants-of-Health-and-Comorbidities-in-Hidradenitis-Suppurativa-Using-an-Inclusive-Database.pdf. Accessed 8 May 2025
- 14.Brydges HT, Onuh OC, Friedman R, Barrett J, Betensky RA, Lu CP, et al. Autoimmune, autoinflammatory disease and cutaneous malignancy associations with hidradenitis suppurativa: a cross-sectional study. Am J Clin Dermatol. 2024;25:473–84. 10.1007/S40257-024-00844-5. [DOI] [PubMed] [Google Scholar]
- 15.Brown ID, Adawi W, Saal R, Perkins-Holtsclaw K, Roberts A. Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study. Clin Exp Dermatol. 2023;48(5):524–7. 10.1093/CED/LLAD034. [DOI] [PubMed] [Google Scholar]
- 16.Tannenbaum R, Strunk A, Garg A. Association between hidradenitis suppurativa and lymphoma. JAMA Dermatol. 2019;155(5):624–5. 10.1001/JAMADERMATOL.2018.5230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Rastogi S, Patel KR, Singam V, Ali Y, Gao J, Amin A, et al. Vulvar cancer association with groin hidradenitis suppurativa: a large, urban, midwestern US patient population study. J Am Acad Dermatol. 2019;80:808–10. 10.1016/j.jaad.2018.10.008. [DOI] [PubMed] [Google Scholar]
- 18.Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71:1144–50. 10.1016/j.jaad.2014.09.012. [DOI] [PubMed] [Google Scholar]
- 19.Sokumbi O, Hodge DO, Ederaine SA, Alavi A, Alikhan A. Comorbid diseases of hidradenitis suppurativa: a 15-year population-based study in Olmsted County, Minnesota, USA. Int J Dermatol. 2022;61:1372–9. 10.1111/IJD.16228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Thakker S, Samynathan A, Bakhshi P, Hochman E, Wikholm C, Pasieka H. 48782 hidradenitis suppurativa-associated cutaneous squamous cell carcinoma: a cross-sectional analysis of the National Inpatient Sample. J Am Acad Dermatol. 2024;91:AB50. 10.1016/j.jaad.2024.07.205. [Google Scholar]
- 21.Bailey AMJ, Li HOY, Tan MG, Kirchhof MG. Association of hidradenitis suppurativa and malignancy: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37:e1107–8. 10.1111/JDV.19136. [DOI] [PubMed] [Google Scholar]
- 22.Racanelli E, Jfri A, Gefri A, O’brien E, Litvinov IV, Zubarev A, et al. Cutaneous squamous cell carcinoma in patients with hidradenitis suppurativa. Cancers (Basel). 2021;13(5):1–12. 10.3390/CANCERS13051153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sohrab SS, Raj R, Nagar A, Hawthorne S, Paiva-Santos AC, Kamal MA, et al. Chronic inflammation’s transformation to cancer: a nanotherapeutic paradigm. Molecules. 2023. 10.3390/molecules28114413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Acharya P, Mathur M. Hidradenitis suppurativa and smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:1006–11. 10.1016/j.jaad.2019.10.044. [DOI] [PubMed] [Google Scholar]
- 25.Garg A, Papagermanos V, Midura M, Strunk A, Merson J. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol. 2018;79:495-500.e1. 10.1016/j.jaad.2018.02.053. [DOI] [PubMed] [Google Scholar]
- 26.Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35:50–61. 10.1111/jdv.16677. [DOI] [PubMed] [Google Scholar]
- 27.Khani Y, Khani Y, Pourgholam-Amiji N, Afshar M, Otroshi O, Sharifi-Esfahani M, et al. Tobacco smoking and cancer types: a review. Biomed Res Ther. 2018;5:2142–59. 10.15419/bmrat.v5i4.428. [Google Scholar]
- 28.Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention? Expert Rev Clin Immunol. 2020;16:479–92. 10.1080/1744666X.2020.1754194. [DOI] [PubMed] [Google Scholar]
- 29.Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–34. 10.1056/NEJMOA1504370. [DOI] [PubMed] [Google Scholar]
- 30.Jourabchi N, Fischer AH, Cimino-Mathews A, Waters KM, Okoye GA. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14(2):435–8. 10.1111/IWJ.12671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Makris GM, Poulakaki N, Papanota AM, Kotsifa E, Sergentanis TN, Psaltopoulou T. Vulvar, perianal and perineal cancer after hidradenitis suppurativa: a systematic review and pooled analysis. Dermatol Surg. 2017;43:107–15. 10.1097/DSS.0000000000000944. [DOI] [PubMed] [Google Scholar]
- 32.Lavogiez C, Delaporte E, Darras-Vercambre S, De Lassalle EM, Castillo C, Mirabel X, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220(2):147–53. 10.1159/000269836. [DOI] [PubMed] [Google Scholar]
- 33.Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77:118–22. 10.1016/j.jaad.2017.02.005. [DOI] [PubMed] [Google Scholar]
- 34.Kailas A, Solomon JA, Mostow EN, Rigel DS, Kittles R, Taylor SC. Gaps in the understanding and treatment of skin cancer in people of color. J Am Acad Dermatol. 2016;74(5):1020–1. 10.1016/j.jaad.2015.11.028. [DOI] [PubMed] [Google Scholar]
- 35.Kaufman BP, Alexis AF. Skin cancer mortality in patients with skin of color. Cutis. 2017;99:307. [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data are available upon reasonable request from the corresponding author.


